Vaxxinity reports Q2 EPS (11c) vs (14c) last year

“Vaxxinity has broken new ground in the first half of 2023. Now in three independent programs, UB-311, UB-312, and UB-313, we have demonstrated proof of technology and our ability to safely induce antibodies in subjects through active immunization. Importantly, we also demonstrated target engagement of toxic forms of alpha-synuclein, a pathology underlying Parkinson’s disease, with UB-312. This is our first clear proof of mechanism of action in patients, showing that UB-312-induced antibodies clearly bind to the target and slow alpha-synuclein aggregation. We expect this to have positive read-through to our Alzheimer’s and other chronic disease programs. In other words, the platform is doing what we designed it to do,” said Mei Mei Hu, CEO of Vaxxinity.